Anindya Mukherjee, Senior Consultant of Medical Oncology at ShardaCare – Healthcity, shared a post on LinkedIn:
“Thank you all for the wonderful participation in the past few days.
No polls today
Here is a practical algorithm tomorrow for neoadjuvant IO in resectable HNSCC:::::
Step 1 – Stage & Site: Resectable stage III–IVA oral cavity / oropharynx / larynx / hypopharynx
Step 2 – Biomarker: Get PD-L1 CPS; if CPS ≥1, consider peri-op pembrolizumab + SoC; if CPS <1, individualise based on risk, cost, access.
Step 3 – Fitness & Logistics: Ensure ECOG 0–1, autoimmune history acceptable, and that you can deliver IO → surgery in ~3 weeks → timely adjuvant RT/CRT
Step 4 – Use classical risk to drive adjuvant intensity, not MPR alone.
Step 5 – Outside of KEYNOTE-689-like patients, keep IO in trials or metastatic setting
Will be initiating discussions on one of the most interesting topics of medical oncology – biomarker guided therapy in NSCLC, from tomorrow.
Stay tuned to this space.”
More posts abut Neoadjuvant IO on OncoDaily.